Purchaser Business Group on Health

The PRO-PM assesses fatigue among adult women with breast cancer entering survivorship after completion of chemotherapy administered with curative intent. Fatigue is assessed using the PROMIS Fatigue 4a scale administered at baseline (prior to chemotherapy) and at follow-up (about three months following completion of chemotherapy). The measure is risk-adjusted.

The PRO-PM assesses pain interference among adult women with breast cancer entering survivorship after completion of chemotherapy administered with curative intent. Pain interference is assessed using the PROMIS Pain Interference 4a scale administered at baseline (prior to chemotherapy) and at follow-up (about three months following completion of chemotherapy). The measure is risk-adjusted.